Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Denosumab effect on breast cell proliferation
NCT02099461Phase 1Completed
- Sponsor
- Amgen
- Start
- Apr 2014
- Primary completion
- Jul 2014
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of denosumab in breast cancer (3 arms), sponsored by Amgen. Primary endpoint: Log Ratio of Post-baseline to Baseline Ki-67 Index in Mammary Epithelial Cells at Day 28. Started Apr 2014; status: completed.
02
Drugs
denosumab
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT02099461.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02099461.